Dr. Taylor Doherty
Dr. Taylor A. Doherty is Professor of Medicine and Chief of the Division of Allergy and Immunology. His studies have led to high-impact publications in the fields of asthma, airway remodeling, aspirin-exacerbated respiratory disease (AERD), and group 2 innate lymphoid cell (ILC2) biology.
About the Lab
Dr. Doherty's research identifies therapeutic targets for chronic asthma and allergic airway disease, focusing on innate type 2 lung responses and novel mechanisms regulating group 2 innate lymphoid cells (ILC2s).
Read More About the LabResearch Highlights
- November 2023, study entitled “Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD” was published in the Journal of Allergy and Clinical Immunology.
- July 2022, study entitled “RNA-binding protein RBM3 intrinsically suppresses lung innate lymphoid cell activation an inflammation partially through CysLT1R” was published in Nature Communications.
- July 2017, study entitled “Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease” was published in the Journal of Allergy and Clinical Immunology. This article was highlighted in the journal’s Editor’s Choice feature.
- August 2017, study entitled “Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation” was published in the Journal of Immunology.
- July 2013, study entitled “Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production” was published in the Journal of Allergy and Clinical Immunology.
- May 2011, study entitled “The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling” was published in Nature Medicine.
Read More About Dr. Doherty's Research